Bosh sahifaAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
2,59 $
Seans yopilganidan keyin:(0,39%)+0,010
2,60 $
Yopilgan:12-sen, 17:07:01 (GMT-4) · USD · NYSEAMERICAN · Ogohlantirish
Yopilish kursi
2,59 $
Kunlik diapazon
2,53 $ - 2,67 $
Yillik diapazon
2,33 $ - 20,35 $
Bozor kapitalizatsiyasi
7,02 mln USD
Oʻrtacha hajm
77,89 ming
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
CNBC
19 soat oldin
S&P 500 fights for another record — plus, Eaton signals big data center opportunity
0,048%
1,62%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 25,00 ming | -50,00% |
Joriy xarajat | 2,66 mln | -28,77% |
Sof foyda | -2,79 mln | -52,18% |
Sof foyda marjasi | -11,18 ming | -204,36% |
Har bir ulushga tushum | -3,68 | -22,67% |
EBITDA | -2,59 mln | 28,68% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 835,00 ming | -91,70% |
Jami aktivlari | 4,13 mln | -73,73% |
Jami passivlari | 10,68 mln | 11,05% |
Umumiy kapital | -6,55 mln | — |
Tarqatilgan aksiyalar | 2,71 mln | — |
Narxi/balansdagi bahosi | -0,30 | — |
Aktivlardan daromad | -127,49% | — |
Kapitaldan daromad | 260,64% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -2,79 mln | -52,18% |
Operatsiyalardan naqd pul | -1,53 mln | 49,10% |
Sarmoyadan naqd pul | 754,00 ming | -8,72% |
Moliyadan naqd pul | 355,00 ming | -85,46% |
Naqd pulning sof oʻzgarishi | -422,00 ming | -262,93% |
Boʻsh pul | -1,37 mln | 65,91% |
Haqida
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Tashkil etilgan
1966
Sayt
Xodimlar soni
22
